Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Author(s): Changjun Chen, Mohammed Alqwbani, Jie Zhao, Ruitong Yang, Songgang Wang* and Xin Pan*

DOI: 10.2174/1871530320999200817114817

DownloadDownload PDF Flyer Cite As
Effects of Teriparatide versus Salmon Calcitonin Therapy for the Treatment of Osteoporosis in Asia: A Meta-analysis of Randomized Controlled Trials

Page: [932 - 942] Pages: 11

  • * (Excluding Mailing and Handling)

Abstract

Objective: The objective of this meta-analysis was to compare the efficacy and safety of teriparatide versus salmon calcitonin for the treatment of osteoporosis in Asian patients and to investigate whether the results of global studies could be applicable to Asian patients.

Methods: PubMed, OVID, Cochrane Central Register of Controlled Trials (CENTRAL) and EMBASE up to December 2018 were searched. Eligible randomized controlled trials (RCTs) that compared teriparatide versus salmon calcitonin in Asian osteoporosis population were included. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used for data synthesis, and Cochrane Collaboration software Review Manager 5.3 was used to analyze the pooled data.

Results: Three RCTs involving 529 patients were included (mean age 68.7 yr; 93.4% females; mean follow-up 6 months); outcome measures included bone mineral density (BMD) of the femoral neck, total hip and lumbar spine; bone markers and adverse events. We found that the period of 6-months of teriparatide treatment was helpful for the improvement of the BMD of lumbar vertebra, however, the improvement of BMD was not significant in the femoral neck and total hip joint. There was a positive correlation between bone-specific alkaline phosphatase (BSAP) and osteocalcin (OCN) and the response of Asian patients to subcutaneous injection of 20 micrograms per day of teriparatide. The proportion of the occurrence of adverse effects was more obvious in the teriparatide group compared with salmon calcitonin, but there was no significant difference.

Conclusion: Results suggested that the use of teriparatide could improve the lumbar BMD by shortterm (six months) application in Asian osteoporosis patients, which is beneficial to the patients who cannot tolerate adverse events of long-term treatment. The BSAP and OCN bone markers could be useful to monitor the responses of Asian osteoporosis patients to teriparatide treatment. Finally, both of teriparatide and salmon calcitonin were well tolerated by Asian patients.

Keywords: Teriparatide, salmon calcitonin, meta-analysis, osteoporosis, Asia, fractures.

Graphical Abstract

[1]
Sleeman, A.; Clements, J.N. Abaloparatide: a new pharmacological option for osteoporosis. Am. J. Health Syst. Pharm., 2019, 76(3), 130-135.
[http://dx.doi.org/10.1093/ajhp/zxy022] [PMID: 30689744]
[2]
Chen, P.; Li, Z.; Hu, Y. Prevalence of osteoporosis in China: a meta-analysis and systematic review. BMC Public Health, 2016, 16(1), 1039.
[http://dx.doi.org/10.1186/s12889-016-3712-7] [PMID: 27716144]
[3]
Lin, X.; Xiong, D.; Peng, Y.Q.; Sheng, Z.F.; Wu, X.Y.; Wu, X.P.; Wu, F.; Yuan, L.Q.; Liao, E.Y. Epidemiology and management of osteoporosis in the People’s Republic of China: current perspectives. Clin. Interv. Aging, 2015, 10, 1017-1033.
[http://dx.doi.org/10.2147/CIA.S54613] [PMID: 26150706]
[4]
Mithal, A.; Kaur, P. Osteoporosis in Asia: a call to action. Curr. Osteoporos. Rep., 2012, 10(4), 245-247.
[http://dx.doi.org/10.1007/s11914-012-0114-3] [PMID: 22898971]
[5]
Dobnig, H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin. Pharmacother., 2004, 5(5), 1153-1162.
[http://dx.doi.org/10.1517/14656566.5.5.1153] [PMID: 15155114]
[6]
Sugimoto, T.; Shiraki, M.; Fukunaga, M.; Hagino, H.; Sone, T.; Nakano, T.; Kishimoto, H.; Ito, M.; Yoshikawa, H.; Kishida, M.; Irie, C.; Nakamura, T. 24-Month open-label teriparatide once-weekly efficacy research trial examining bone mineral density in subjects with primary osteoporosis and high fracture risk. Adv. Ther., 2017, 34(7), 1727-1740.
[http://dx.doi.org/10.1007/s12325-017-0568-x] [PMID: 28631217]
[7]
Muñoz-Torres, M.; Alonso, G.; Raya, M.P. Calcitonin therapy in osteoporosis. Treat. Endocrinol., 2004, 3(2), 117-132 [J]..
[http://dx.doi.org/10.2165/00024677-200403020-00006] [PMID: 15743107]
[8]
Binkley, N.; Bolognese, M.; Sidorowicz-Bialynicka, A.; Vally, T.; Trout, R.; Miller, C.; Buben, C.E.; Gilligan, J.P.; Krause, D.S. Oral calcitonin in postmenopausal osteoporosis (ORACAL) investigators. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (ORACAL) trial. J. Bone Miner. Res., 2012, 27(8), 1821-1829.
[http://dx.doi.org/10.1002/jbmr.1602] [PMID: 22437792]
[9]
Henriksen, K.; Bay-Jensen, A.C.; Christiansen, C.; Karsdal, M.A. Oral salmon calcitonin--pharmacology in osteoporosis. Expert Opin. Biol. Ther., 2010, 10(11), 1617-1629.
[http://dx.doi.org/10.1517/14712598.2010.526104] [PMID: 20932224]
[10]
Papadokostakis, G.; Damilakis, J.; Mantzouranis, E.; Katonis, P.; Hadjipavlou, A. The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur. Spine J., 2006, 15(3), 356-362.
[http://dx.doi.org/10.1007/s00586-005-0916-4] [PMID: 16193299]
[11]
Johnell, O.; Kanis, J.A.; Oden, A.; Johansson, H.; De Laet, C.; Delmas, P.; Eisman, J.A.; Fujiwara, S.; Kroger, H.; Mellstrom, D.; Meunier, P.J.; Melton, L.J., III; O’Neill, T.; Pols, H.; Reeve, J.; Silman, A.; Tenenhouse, A. Predictive value of BMD for hip and other fractures. J. Bone Miner. Res., 2005, 20(7), 1185-1194.
[http://dx.doi.org/10.1359/JBMR.050304] [PMID: 15940371]
[12]
Garnero, P. Biomarkers for osteoporosis management: utility in diagnosis, fracture risk prediction and therapy monitoring. Mol. Diagn. Ther., 2008, 12(3), 157-170.
[http://dx.doi.org/10.1007/BF03256280] [PMID: 18510379]
[13]
Scudeller, L A; Srinivasan, S; Rossi, A.M. Orientation and conformation of osteocalcin adsorbed onto calcium phosphate and silica surfaces., Biointerphases, 2017, 12(2), 02D411..
[http://dx.doi.org/10.1116/1.4983407] [PMID: 28521505]
[14]
Tanabe, R.; Kawamura, Y.; Tsugawa, N.; Haraikawa, M.; Sogabe, N.; Okano, T.; Hosoi, T.; Goseki-Sone, M. Effects of Fok-I polymorphism in vitamin D receptor gene on serum 25-hydroxyvitamin D, bone-specific alkaline phosphatase and calcaneal quantitative ultrasound parameters in young adults. Asia Pac. J. Clin. Nutr., 2015, 24(2), 329-335.
[http://dx.doi.org/10.6133/apjcn.2015.24.2.01] [PMID: 26078251]
[15]
Tripathi, T.; Gupta, P.; Sharma, J.; Rai, P.; Gupta, V.K.; Singh, N. Bone-specific alkaline phosphatase - a potential biomarker for skeletal growth assessment. J. Orthod., 2018, 45(1), 4-10.
[http://dx.doi.org/10.1080/14653125.2017.1416571] [PMID: 29281939]
[16]
Eastell, R.; Szulc, P. Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes Endocrinol., 2017, 5(11), 908-923.
[http://dx.doi.org/10.1016/S2213-8587(17)30184-5] [PMID: 28689768]
[17]
Liberati, A.; Altman, D.G.; Tetzlaff, J.; Mulrow, C.; Gøtzsche, P.C.; Ioannidis, J.P.; Clarke, M.; Devereaux, P.J.; Kleijnen, J.; Moher, D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med., 2009, 6(7)e1000100
[http://dx.doi.org/10.1371/journal.pmed.1000100] [PMID: 19621070]
[18]
Hozo, S.P.; Djulbegovic, B.; Hozo, I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med. Res. Methodol., 2005, 5, 13.
[http://dx.doi.org/10.1186/1471-2288-5-13] [PMID: 15840177]
[19]
Cumpston, M.; Li, T.; Page, M.J.; Chandler, J.; Welch, V.A.; Higgins, J.P.; Thomas, J. Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst. Rev., 2019, 10ED000142
[http://dx.doi.org/10.1002/14651858.ED000142] [PMID: 31643080]
[20]
Kung, A.W.; Pasion, E.G.; Sofiyan, M.; Lau, E.M.; Tay, B.K.; Lam, K.S.; Wilawan, K.; Ongphiphadhanakul, B.; Thiebaud, D. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr. Med. Res. Opin., 2006, 22(5), 929-937.
[http://dx.doi.org/10.1185/030079906X104768] [PMID: 16709314]
[21]
Hwang, J.S.; Tu, S.T.; Yang, T.S.; Chen, J.F.; Wang, C.J.; Tsai, K.S. Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos. Int., 2006, 17(3), 373-378.
[http://dx.doi.org/10.1007/s00198-005-2002-5] [PMID: 16421647]
[22]
Lu, C.; Chen, Y.; Zhang, B.; Chen, Y.; Bai, F.; Chen, D. Response to teriparatide in Chinese patients with established osteoporosis: osteocalcin and lumbar spine bone-mineral density changes from teriparatide Phase III study. Clin. Interv. Aging, 2017, 12, 1717-1723.
[http://dx.doi.org/10.2147/CIA.S140900] [PMID: 29066877]
[23]
Kim, S.Y.; Zhang, M.; Bockman, R. Bone mineral density response from teriparatide in patients with osteoporosis. HSS J., 2017, 13(2), 171-177.
[http://dx.doi.org/10.1007/s11420-016-9537-1] [PMID: 28690468]
[24]
Fahrleitner-Pammer, A.; Langdahl, B.L.; Marin, F.; Jakob, F.; Karras, D.; Barrett, A.; Ljunggren, Ö.; Walsh, J.B.; Rajzbaum, G.; Barker, C.; Lems, W.F. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos. Int., 2011, 22(10), 2709-2719.
[http://dx.doi.org/10.1007/s00198-010-1498-5] [PMID: 21113576]
[25]
Eastell, R.; Nickelsen, T.; Marin, F.; Barker, C.; Hadji, P.; Farrerons, J.; Audran, M.; Boonen, S.; Brixen, K.; Gomes, J.M.; Obermayer-Pietsch, B.; Avramidis, A.; Sigurdsson, G.; Glüer, C.C. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J. Bone Miner. Res., 2009, 24(4), 726-736.
[http://dx.doi.org/10.1359/jbmr.081215] [PMID: 19049337]
[26]
An, J.; Yang, H.; Zhang, Q.; Liu, C.; Zhao, J.; Zhang, L.; Chen, B. Natural products for treatment of osteoporosis: The effects and mechanisms on promoting osteoblast-mediated bone formation. Life Sci., 2016, 147, 46-58.
[http://dx.doi.org/10.1016/j.lfs.2016.01.024] [PMID: 26796578]
[27]
Karpf, D.B.; Pihl, S.; Mourya, S.; Mortensen, E.; Kovoor, E.; Markova, D.; Leff, J.A. A Randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults. J. Bone Miner. Res., 2020, 35(8), 1430-1440.
[http://dx.doi.org/10.1002/jbmr.4016] [PMID: 32212275]
[28]
Raterman, H.G.; Bultink, I.E.M.; Lems, W.F. Current treatments and new developments in the management of glucocorticoid-induced osteoporosis. Drugs, 2019, 79(10), 1065-1087.
[http://dx.doi.org/10.1007/s40265-019-01145-6] [PMID: 31201710]
[29]
Galluccio, F.; Matucci-Cerinic, M. Efficacy of short-term teriparatide for hip osteonecrosis. J. Rheumatol., 2016, 43(11), 2084-2085.
[http://dx.doi.org/10.3899/jrheum.160190] [PMID: 27803352]
[30]
Obermayer-Pietsch, B.M.; Marin, F.; McCloskey, E.V.; Hadji, P.; Farrerons, J.; Boonen, S.; Audran, M.; Barker, C.; Anastasilakis, A.D.; Fraser, W.D.; Nickelsen, T. EUROFORS investigators. Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J. Bone Miner. Res., 2008, 23(10), 1591-1600.
[http://dx.doi.org/10.1359/jbmr.080506] [PMID: 18505369]
[31]
Chesnut, C.H., III; Azria, M.; Silverman, S.; Engelhardt, M.; Olson, M.; Mindeholm, L. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporos. Int., 2008, 19(4), 479-491.
[http://dx.doi.org/10.1007/s00198-007-0490-1] [PMID: 18071651]
[32]
Blick, S.K.; Dhillon, S.; Keam, S.J. Teriparatide: a review of its use in osteoporosis. Drugs, 2008, 68(18), 2709-2737.
[http://dx.doi.org/10.2165/0003495-200868180-00012] [PMID: 19093708]
[33]
Bandeira, L.; Lewiecki, E.M.; Bilezikian, J.P. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis. Expert Opin. Drug Metab. Toxicol., 2016, 12(6), 681-689.
[http://dx.doi.org/10.1080/17425255.2016.1175436] [PMID: 27070719]
[34]
Tanaka, S.; Kuroda, T.; Sugimoto, T.; Nakamura, T.; Shiraki, M. Changes in bone mineral density, bone turnover markers, and vertebral fracture risk reduction with once weekly teriparatide. Curr. Med. Res. Opin., 2014, 30(5), 931-936.
[http://dx.doi.org/10.1185/03007995.2013.879440] [PMID: 24392946]
[35]
Lindsay, R.; Krege, J.H.; Marin, F.; Jin, L.; Stepan, J.J. Teriparatide for osteoporosis: importance of the full course. Osteoporos. Int., 2016, 27(8), 2395-2410.
[http://dx.doi.org/10.1007/s00198-016-3534-6] [PMID: 26902094]
[36]
Chesnut, C.H., III; Majumdar, S.; Newitt, D.C.; Shields, A.; Van Pelt, J.; Laschansky, E.; Azria, M.; Kriegman, A.; Olson, M.; Eriksen, E.F.; Mindeholm, L. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. J. Bone Miner. Res., 2005, 20(9), 1548-1561.
[http://dx.doi.org/10.1359/JBMR.050411] [PMID: 16059627]
[37]
Kleerekoper, M.; Greenspan, S.L.; Lewiecki, E.M.; Miller, P.D.; Kendler, D.L.; Maricic, M.; Keaveny, T.M.; Kopperdahl, D.L.; Ruff, V.A.; Wan, X.; Janos, B.; Krohn, K. Assessing the effects of teriparatide treatment on bone mineral density, bone microarchitecture, and bone strength. J. Bone Joint Surg. Am., 2014, 96(11)e90
[http://dx.doi.org/10.2106/JBJS.L.01757] [PMID: 24897747]
[38]
Yamamoto, T.; Taketsuna, M.; Guo, X.; Sato, M.; Sowa, H. The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report. J. Bone Miner. Metab., 2014, 32(6), 699-708.
[http://dx.doi.org/10.1007/s00774-013-0546-6] [PMID: 24368586]